Participated · Series C · May 2026

Quantum Motion develops full-stack quantum computers built on silicon chip technology, claiming potential reductions of roughly 100-fold in cost and space requirements and 1,000-fold in energy consumption compared with some rivals. The company was founded in 2017 by Professor John Morton and Professor Simon Benjamin and is led by CEO James Palles-Dimmock. Headquartered in London, Quantum Motion also operates offices and labs in Spain, Australia and the US. Financially, the startup has raised over $200M to date, including a recent $160M Series C. The new funding is earmarked for commercialisation, continued research and development, and geographic expansion as the company scales its platform.

Participated · Series B · Mar 2026

Founded in 2019, Silverflow offers a cloud-based card payment processing solution that connects directly to networks such as Visa, Mastercard, American Express, Diners Club and Discover through one API. The platform delivers real-time data insights and features including 3D Secure, network tokenisation, direct-to-card payouts, and a dispute-management portal. Over the last two and a half years, the company has scaled daily transaction volume from roughly 180 to about 1.75 million, putting it on track to process nearly one billion transactions annually. Silverflow’s customers include Deutsche Bank, Bolt, Payabl., and Buckaroo, spanning Europe, North America, and APAC. With the new capital, it plans to expand headcount by more than 50 percent (from 85 to ~120 employees) and deepen its presence in North America and Southeast Asia. Product plans call for adding support for China UnionPay and JCB, building new front-end tools, and extending capabilities to in-store payments. The company positions itself as the modern alternative to legacy payment processors, aiming to simplify complexity and speed time-to-market for its clients.

Participated · Series A · Dec 2025

TargED Biopharmaceuticals B.V., founded in 2020 as a spin-out from University Medical Center Utrecht, is focused on TGD001, an antibody-enzyme fusion protein that binds von Willebrand factor (VWF) and degrades both VWF and fibrin to dissolve clots. The therapy has completed a Phase 1 first-in-human study that showed a favorable safety profile with no spontaneous bleeding events and potent thrombolytic activity. With its latest funding, the company will initiate two Phase 1/2 clinical studies targeting acute ischemic stroke and thrombotic microangiopathies, expanding trial sites across Europe and the U.S. and aiming for first data in 2026. Unlike approved thrombolytics that target a single pathway, TGD001 leverages the ubiquitous presence of VWF to enable broad clot dissolution. TargED has raised over €60 million in Series A financing to date and also received a blended-finance grant from the European Innovation Council Accelerator in 2025. The fresh capital strengthens its balance sheet and accelerates clinical development toward demonstrating proof-of-concept in multiple life-threatening indications.

Participated · Series B · May 2025

Salvia BioElectronics is developing MySalvia Therapy, an implantable neuromodulation system aimed at reducing the frequency and severity of chronic migraine attacks. The system uses two ultra-thin implants placed under the skin of the forehead and back of the head, activated on demand by an external wearable device, and is designed to be patient-controlled and minimally invasive. Salvia holds FDA Breakthrough Device Designation and is conducting the multi-center, double-blind, sham-controlled RECLAIM trial in Europe and Australia, with U.S. trials planned. The company says its approach targets patients who have not responded well to conventional therapies, addressing a large unmet need given migraine's substantial economic and disability burden. Salvia plans to use new capital to complete the RECLAIM study, pursue regulatory filings, and prepare for commercial launches in the United States, Europe, and Australia. It recently closed a $60M Series B to support those efforts, backed by a syndicate of investors. Salvia BioElectronics develops a neuromodulation platform that uses highly conforming bioelectronic foils designed to be inserted below the skin in a minimally invasive procedure to target known neural targets in chronic migraine. The company aims to translate proven neurostimulation therapy into an implantable form factor that is compatible with head anatomy, with the ambition of delivering a therapy as easy as taking medication and side-effect free. Salvia was founded in 2017 by neuromodulation industry veterans and is based in Eindhoven, the Netherlands. The startup emphasizes safety, effectiveness, affordability, and completing therapy development toward market entry. Management positions the approach as addressing an unmet need because there are currently no approved implantable devices for chronic migraine despite neurostimulation’s demonstrated effectiveness. The recent financing provides capital to advance product development and regulatory progress toward commercialization.

Participated · Seed · Jul 2024

Draupnir Bio is harnessing the natural machinery of the lysosome to develop oral, small-molecule degraders that target extracellular disease-causing proteins. The company’s approach targets both validated proteins and targets traditionally difficult to drug. It was spun out from Aarhus University and the Max-Planck Society and is based in Copenhagen, Denmark. Led by CEO Andrew Hotchkiss, Draupnir is advancing a risk-diversified preclinical pipeline of oral protein degraders. The company completed a €12M Seed financing to support further development of that pipeline. No operating metrics were disclosed in the article.